MedTrace Logo

Allogeneic Adipose Tissue-derived Mesenchymal Stem Cells in Ischemic Stroke

NCT04280003 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-05-30

No results posted yet for this study

Summary

This is a multicenter, doble blind, placebo controlled clinical trial to asses de safety and efficacy of intravenous administration of alogenic adipose tissue-derived mesenchymal stem cells in the first four days from acute ischemic stroke.

Conditions

Interventions

OTHER

Alogenic adipose tissue-derived stem cells

Concentration of the cells: 10 million cells / ml

DRUG

Placebo solution

Placebo intravenous solution, same appearance stem cells solution

Sponsors & Collaborators

  • Instituto de Investigación Hospital Universitario La Paz

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-20
Primary Completion
2023-07-15
Completion
2023-07-15

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04280003 on ClinicalTrials.gov